Voya Investment Management LLC Raises Holdings in Mineralys Therapeutics, Inc. $MLYS

Voya Investment Management LLC lifted its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 174.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,526 shares of the company’s stock after buying an additional 88,050 shares during the quarter. Voya Investment Management LLC’s holdings in Mineralys Therapeutics were worth $5,253,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Mineralys Therapeutics by 42.1% in the first quarter. Vanguard Group Inc. now owns 2,035,506 shares of the company’s stock worth $32,324,000 after acquiring an additional 603,464 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Mineralys Therapeutics by 25.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 270,175 shares of the company’s stock valued at $4,290,000 after purchasing an additional 55,269 shares in the last quarter. Invesco Ltd. purchased a new stake in shares of Mineralys Therapeutics in the 1st quarter worth approximately $4,896,000. Nuveen LLC purchased a new stake in shares of Mineralys Therapeutics in the 1st quarter worth approximately $1,078,000. Finally, Wellington Management Group LLP boosted its stake in shares of Mineralys Therapeutics by 32.8% during the first quarter. Wellington Management Group LLP now owns 121,557 shares of the company’s stock valued at $1,930,000 after purchasing an additional 30,028 shares in the last quarter. 84.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Mineralys Therapeutics news, CEO Jon Congleton sold 200,000 shares of the firm’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $45.44, for a total value of $9,088,000.00. Following the completion of the transaction, the chief executive officer owned 631,305 shares of the company’s stock, valued at approximately $28,686,499.20. This trade represents a 24.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Daphne Karydas sold 15,000 shares of Mineralys Therapeutics stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $45.99, for a total transaction of $689,850.00. The SEC filing for this sale provides additional information. Insiders sold 1,405,426 shares of company stock worth $61,610,431 over the last ninety days. Company insiders own 25.56% of the company’s stock.

Mineralys Therapeutics Price Performance

Mineralys Therapeutics stock opened at $37.44 on Friday. Mineralys Therapeutics, Inc. has a 1-year low of $8.24 and a 1-year high of $47.65. The business has a fifty day moving average price of $40.33 and a 200-day moving average price of $28.78. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of -12.69 and a beta of 0.40.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. On average, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on MLYS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Wednesday, October 8th. HC Wainwright boosted their price target on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Stifel Nicolaus raised their price objective on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, December 19th. The Goldman Sachs Group lifted their target price on Mineralys Therapeutics from $32.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, September 9th. Finally, Wells Fargo & Company boosted their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Mineralys Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $47.43.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.